The Journal of Rheumatology · 2012 · 47 citations · 24 references
MedicineClinical SciencesPharmacotherapyDisability ManagementRehabilitationRheumatologyAutoimmune Rheumatic DiseasesChronic DiseaseChronic Disease PharmacotherapyFatigueResponse AssessmentRheumatoid ArthritisDisease-related FatigueFatigue BurdenPhysical Function AssessmentPhysical Function MeasurementPlacebo-controlled Efficacy AssessmentRefractory Rheumatoid ArthritisRheumatoid Arthritis PharmacotherapyRheumatoid Arthritis Therapy
OBJECTIVE: To evaluate the effect of golimumab on physical function, general health, and fatigue in patients with active rheumatoid arthritis (RA) despite methotrexate (MTX) therapy. METHODS: In the multicenter, randomized, placebo-controlled GO-FORWARD study, 444 adults with active RA despite MTX received subcutaneous placebo + MTX (crossover to golimumab 50 mg at Week 24), golimumab 100 mg + placebo, golimumab 50 mg + MTX, or golimumab 100 mg + MTX every 4 weeks. Physical function and general health were assessed using the Health Assessment Questionnaire-Disability Index (HAQ-DI) and Physical and Mental Component Summary (PCS, MCS) scores of the Medical Outcomes Study Short Form-36 questionnaire (SF-36), respectively, through Week 52. Fatigue was measured through Week 24 using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire. RESULTS: Mean improvements from baseline in HAQ-DI, SF-36 PCS, and FACIT-Fatigue scores (Weeks 14 and 24) were significantly greater for golimumab 50 mg + MTX and 100 mg + MTX versus placebo + MTX. Significantly greater proportions of patients treated with golimumab + MTX achieved clinically meaningful improvements from baseline to Weeks 14 and 24 in HAQ-DI, PCS, and FACIT-Fatigue scores. Mean improvements in SF-36 PCS (Week 14), MCS (Week 24), and FACIT-Fatigue (Weeks 14 and 24) scores were significantly greater for golimumab 100 mg + placebo versus placebo + MTX. Mean improvements from baseline in HAQ-DI, SF-36 PCS, and MCS scores through Week 24 were sustained through Week 52. CONCLUSION: Patients with active RA despite MTX had significant improvement in physical function, general health, and fatigue following golimumab + MTX therapy; improvements in physical function and general health were maintained through Week 52. (Clinical Trials Registration NCT00264550).
24
The MOS 36-ltem Short-Form Health Survey (SF-36)
John E. Ware, Cathy D. Sherbourne · Medical Care · 1992 · 29.8K citations
Measurement of patient outcome in arthritis
James F. Fries, Patricia W. Spitz, R. Guy Kraines et al. · Arthritis & Rheumatism · 1980 · 4.4K citations
Lars Klareskog, Désirée van der Heijde, J Jäger et al. · The Lancet · 2004 · 1.8K citations